Assembly Biosciences, Inc. (NASDAQ:ASMB – Get Free Report) major shareholder Alexander Schornstein purchased 10,000 shares of the firm’s stock in a transaction dated Tuesday, October 8th. The stock was purchased at an average cost of $14.58 per share, with a total value of $145,800.00. Following the acquisition, the insider now directly owns 703,113 shares in the company, valued at $10,251,387.54. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Assembly Biosciences Stock Up 3.9 %
Shares of ASMB stock traded up $0.56 during trading hours on Wednesday, hitting $14.98. 5,450 shares of the company were exchanged, compared to its average volume of 22,747. Assembly Biosciences, Inc. has a 52 week low of $7.69 and a 52 week high of $20.04. The business has a 50 day moving average of $15.54 and a two-hundred day moving average of $14.69.
Assembly Biosciences (NASDAQ:ASMB – Get Free Report) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.96) by $0.98. The firm had revenue of $8.53 million for the quarter, compared to the consensus estimate of $5.96 million. As a group, equities research analysts predict that Assembly Biosciences, Inc. will post -7.82 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Assembly Biosciences
Analyst Ratings Changes
ASMB has been the subject of a number of research analyst reports. HC Wainwright reissued a “neutral” rating on shares of Assembly Biosciences in a research note on Tuesday, September 24th. Jefferies Financial Group upgraded Assembly Biosciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $2.00 to $35.00 in a research report on Friday, September 20th.
View Our Latest Analysis on ASMB
Assembly Biosciences Company Profile
Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
Further Reading
- Five stocks we like better than Assembly Biosciences
- Health Care Stocks Explained: Why You Might Want to Invest
- Insiders Hold Tight as Helen of Troy Prepares for a Major Rebound
- Using the MarketBeat Dividend Tax Calculator
- Is SelectQuote a Double-Bagger Stock? Analysts Predict Huge Gains
- There Are Different Types of Stock To Invest In
- This Major Sell-Off in Chinese Stocks Could Be Your Buy Signal
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.